

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**FOSUNPHARMA**  
**复星医药**

上海復星醫藥（集團）股份有限公司  
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

(Stock Code: 02196)

**FOSUN 复星**

復星國際有限公司  
**FOSUN INTERNATIONAL LIMITED**

*(Incorporated in Hong Kong with limited liability)*

(Stock Code: 00656)

## **JOINT ANNOUNCEMENT DISCLOSEABLE TRANSACTION — PROGRESS ON ACQUISITION OF THE CONTROLLING INTEREST IN GLAND PHARMA LIMITED**

References are made to the joint announcements dated 28 July 2016 and 24 April 2017 of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (“**Fosun Pharma**”) and Fosun International Limited (“**Fosun International**”), the controlling shareholder of Fosun Pharma, the announcements of Fosun Pharma dated 4 August 2016 and 30 March 2017 and the circular of Fosun Pharma dated 11 August 2016 (the “**Circular**”) and the poll results announcement of Fosun Pharma dated 29 September 2016 in connection with, among other things, acquiring approximately 86.08% equity interest in Gland Pharma Limited. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Circular.

### **PROGRESS ON THE ACQUISITION**

As at the date of this announcement, the approvals of the relevant PRC authorities in respect of the Acquisition have been obtained and the United States anti-trust filings and the Indian anti-trust filings have been completed. In addition, the Acquisition was reviewed by the Indian Foreign Investment Promotion Board, which has been recommended to the Cabinet Committee on Economic Affairs of India for further review.

Since the Acquisition is still subject to the review and approval of the Cabinet Committee on Economic Affairs of India, on 27 July 2017, Fosun Pharma, the Buyer, KKR, the Founder Shareholders and the Target Company entered into the Amendment No. 2 to the Share Purchase Agreement (the “**Amendment No. 2**”), pursuant to which the parties agreed to further extend the Termination Date to 26 September 2017. Except for the extension of the Termination Date provided in the Amendment No. 2, other terms of the Share Purchase Agreement will not be amended, modified or supplemented. The Amendment No. 2 shall form an integral part of the Share Purchase Agreement.

**Shareholders and potential investors of Fosun Pharma and Fosun International should note that the completion of the Acquisition is still subject to the approval of the Cabinet Committee on Economic Affairs of India and the completion of relevant formalities. Shareholders and potential investors of Fosun Pharma and Fosun International are reminded to exercise caution when dealing in the securities of each of Fosun Pharma and Fosun International.**

By order of the Board  
**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***  
**Chen Qiyu**  
*Chairman*

By order of the board  
**Fosun International Limited**  
**Guo Guangchang**  
*Chairman*

27 July 2017

*As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of Fosun Pharma are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive directors of Fosun Pharma are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.*

*As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetao, Mr. Wang Can, Ms. Kang Lan and Mr. Gong Ping; and the independent non-executive directors of Fosun International are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.*

\* *for identification purposes only*